After a $134M IPO, Seres settles into a new R&D shop

Seres Therapeutics ($MCRB), one of the year's IPO success stories, has leased an 83,000-square-foot R&D outpost in its native Cambridge, MA, pressing forward with a pipeline of microbiome treatments. As the Boston Business Journal reports, Seres has signed up to become the final tenant in a BioMed Realty-owned building that is also home to AbbVie ($ABBV), CRISPR Therapeutics, Synlogic and RaNA Therapeutics. Seres is in Phase II with SER-109, a Tylenol-sized capsule designed to treat recurrent Clostridium difficile infections by changing patients' bacterial makeup. Story

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera